Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Clinical trial

NCT06618287

1 development in the corpus

NCT06618287

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · PHASE 1/2 TRIAL

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

ClinicalTrials.gov

This is an ongoing Phase 1/2 trial registration with no results reported; it describes planned safety and tolerability endpoints in a combination drug study for advanced solid tumors.

PreliminaryNivolumab Osimertinib BMS-986507

Reported

Planned enrollment416

Study phasePhase 1, Phase 2

DLT evaluation periodUp to 3 weeks

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support